发布求助
文献互助 智能选刊 最新文献

Allergy最新文献

筛选
英文 中文
FDA approves first schizophrenia drug with new mechanism of action since 1950s 美国食品和药物管理局批准自 20 世纪 50 年代以来首款具有新作用机制的精神分裂症药物
IF 122.7 1区 医学
Allergy Pub Date : 2024-09-26 DOI: 10.1038/d41573-024-00155-8
Katie Kingwell
{"title":"FDA approves first schizophrenia drug with new mechanism of action since 1950s","authors":"Katie Kingwell","doi":"10.1038/d41573-024-00155-8","DOIUrl":"10.1038/d41573-024-00155-8","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 11","pages":"803-803"},"PeriodicalIF":122.7,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142321936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A tale of two ecosystems: the biopharma landscape in China and India 两个生态系统的故事：中国和印度的生物制药格局
IF 122.7 1区 医学
Allergy Pub Date : 2024-09-25 DOI: 10.1038/d41573-024-00152-x
Ajay Gautam
{"title":"A tale of two ecosystems: the biopharma landscape in China and India","authors":"Ajay Gautam","doi":"10.1038/d41573-024-00152-x","DOIUrl":"10.1038/d41573-024-00152-x","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 11","pages":"807-807"},"PeriodicalIF":122.7,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142317057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting neurofibrosis reverses metabolic dysfunction 以神经纤维化为目标可逆转代谢功能障碍
IF 122.7 1区 医学
Allergy Pub Date : 2024-09-25 DOI: 10.1038/d41573-024-00156-7
Sarah Crunkhorn
{"title":"Targeting neurofibrosis reverses metabolic dysfunction","authors":"Sarah Crunkhorn","doi":"10.1038/d41573-024-00156-7","DOIUrl":"10.1038/d41573-024-00156-7","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 11","pages":"813-813"},"PeriodicalIF":122.7,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142317056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Agonist antibody lowers blood pressure 激动剂抗体可降低血压
IF 122.7 1区 医学
Allergy Pub Date : 2024-09-23 DOI: 10.1038/d41573-024-00151-y
Alex Eccleston
{"title":"Agonist antibody lowers blood pressure","authors":"Alex Eccleston","doi":"10.1038/d41573-024-00151-y","DOIUrl":"10.1038/d41573-024-00151-y","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 11","pages":"815-815"},"PeriodicalIF":122.7,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142276784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Publisher Correction: Strategies to therapeutically modulate cytokine action 出版商更正：调节细胞因子作用的治疗策略。
IF 122.7 1区 医学
Allergy Pub Date : 2024-09-20 DOI: 10.1038/s41573-024-01055-7
Warren J. Leonard, Jian-Xin Lin
{"title":"Publisher Correction: Strategies to therapeutically modulate cytokine action","authors":"Warren J. Leonard, Jian-Xin Lin","doi":"10.1038/s41573-024-01055-7","DOIUrl":"10.1038/s41573-024-01055-7","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 11","pages":"880-880"},"PeriodicalIF":122.7,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41573-024-01055-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vivo CAR T cells move into clinical trials 体内 CAR T 细胞进入临床试验阶段
IF 122.7 1区 医学
Allergy Pub Date : 2024-09-16 DOI: 10.1038/d41573-024-00150-z
Asher Mullard
{"title":"In vivo CAR T cells move into clinical trials","authors":"Asher Mullard","doi":"10.1038/d41573-024-00150-z","DOIUrl":"10.1038/d41573-024-00150-z","url":null,"abstract":"Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity. Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 10","pages":"727-730"},"PeriodicalIF":122.7,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142235218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Creating an AI-first drug discovery engine 创建人工智能药物发现引擎
IF 122.7 1区 医学
Allergy Pub Date : 2024-09-13 DOI: 10.1038/d41573-024-00149-6
Asher Mullard
{"title":"Creating an AI-first drug discovery engine","authors":"Asher Mullard","doi":"10.1038/d41573-024-00149-6","DOIUrl":"10.1038/d41573-024-00149-6","url":null,"abstract":"Najat Khan — Chief R&D Officer and Chief Commercial Officer at Recursion — discusses the proposed merger of Recursion and Exscientia. Najat Khan — Chief R&D Officer and Chief Commercial Officer at Recursion — discusses the proposed merger of Recursion and Exscientia.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 10","pages":"734-735"},"PeriodicalIF":122.7,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Antimalarial drug discovery: progress and approaches 作者更正：抗疟药物的发现：进展与方法。
IF 122.7 1区 医学
Allergy Pub Date : 2024-09-13 DOI: 10.1038/s41573-024-01045-9
Jair L. Siqueira-Neto, Kathryn J. Wicht, Kelly Chibale, Jeremy N. Burrows, David A. Fidock, Elizabeth A. Winzeler
{"title":"Author Correction: Antimalarial drug discovery: progress and approaches","authors":"Jair L. Siqueira-Neto, Kathryn J. Wicht, Kelly Chibale, Jeremy N. Burrows, David A. Fidock, Elizabeth A. Winzeler","doi":"10.1038/s41573-024-01045-9","DOIUrl":"10.1038/s41573-024-01045-9","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 11","pages":"880-880"},"PeriodicalIF":122.7,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41573-024-01045-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142233478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting cytokine networks in neuroinflammatory diseases 针对神经炎性疾病中的细胞因子网络
IF 122.7 1区 医学
Allergy Pub Date : 2024-09-11 DOI: 10.1038/s41573-024-01026-y
Burkhard Becher, Tobias Derfuss, Roland Liblau
{"title":"Targeting cytokine networks in neuroinflammatory diseases","authors":"Burkhard Becher, Tobias Derfuss, Roland Liblau","doi":"10.1038/s41573-024-01026-y","DOIUrl":"10.1038/s41573-024-01026-y","url":null,"abstract":"In neuroinflammatory diseases, systemic (blood-borne) leukocytes invade the central nervous system (CNS) and lead to tissue damage. A causal relationship between neuroinflammatory diseases and dysregulated cytokine networks is well established across several preclinical models. Cytokine dysregulation is also observed as an inadvertent effect of cancer immunotherapy, where it often leads to neuroinflammation. Neuroinflammatory diseases can be separated into those in which a pathogen is at the centre of the immune response and those of largely unknown aetiology. Here, we discuss the pathophysiology, cytokine networks and therapeutic landscape of ‘sterile’ neuroinflammatory diseases such as multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), neurosarcoidosis and immune effector cell-associated neurotoxicity syndrome (ICANS) triggered by cancer immunotherapy. Despite successes in targeting cytokine networks in preclinical models of neuroinflammation, the clinical translation of targeting cytokines and their receptors has shown mixed and often paradoxical responses. Dysregulated cytokine networks are important in the pathogenesis of neuroinflammation. This Review discusses targeting cytokines and their receptors in non-infectious central nervous system inflammatory diseases such as multiple sclerosis and neurosarcoidosis, as well as in the neurotoxic adverse events that can be triggered by cancer immunotherapy.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 11","pages":"862-879"},"PeriodicalIF":122.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142166599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Upcoming market catalysts in Q4 2024 2024 年第四季度即将出现的市场催化剂
IF 122.7 1区 医学
Allergy Pub Date : 2024-09-10 DOI: 10.1038/d41573-024-00148-7
Sarina Harper
{"title":"Upcoming market catalysts in Q4 2024","authors":"Sarina Harper","doi":"10.1038/d41573-024-00148-7","DOIUrl":"10.1038/d41573-024-00148-7","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 10","pages":"733-733"},"PeriodicalIF":122.7,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142160588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信